Rosiglitazone: Possible complications and treatment of non-alcoholic steatohepatitis (NASH)

Journal of Hepatology

Volumn 48, Issue 1, 2008, Pages 174-176

  Henriksen, Jens H ^a   Ring Larsen, Helmer ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

ADD ON THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFECT; ELECTROCARDIOGRAM; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HEART INFARCTION; HOSPITALIZATION; HUMAN; LIVER TOXICITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; QT INTERVAL;

EID: 36749101992     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.10.004     Document Type: Article

References (13)

1. Trappoliere M., Tuccillo C., Federico A., Di Leva A., Niosi M., D'Alessio C., et al. The treatment of NAFLD. Eur Rev Pharmacol Sci 9 (2005) 299-304
2. Harrison S.A. New treatments for non-alcoholic fatty liver disease. Curr Gastroenterol Rep 8 (2006) 21-29
3. Chejfec G. Fat replacement of the glycogen in the liver as a cause of death. Arch Pathol Lab Med 125 (2001) 21-24
4. Siebler J., and Galle P.R. Treatment of non-alcoholic fatty liver disease. World J Gastroenterol 12 (2006) 2161-2167
5. Einhorn D., Aroda V.R., and Henry R.R. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin North Am 33 (2004) 595-616
6. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved non-alcoholic steatohepatitis after 48 weeks of treatment with PPAR-gamma ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
7. Zhu X.X., Pan C.Y., Li G.W., Shi H.L., Tian H., Yang W.Y., et al. Addition of rosiglitazone to existing sulfonylurea treatment in Chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diabetes Technol Ther 5 (2003) 33-42
8. Wang C.H., Leung C.H., Liu S.C., and Chung C.H. Safety and effectiveness of rosiglitazone in type 2 diabetes patients with non-alcoholic fatty liver disease. J Formos Med Assoc 105 (2006) 743-752
9. Akyuz F., Demir K., Ozdil S., Aksoy N., Poturoglu S., Ibrisim D., et al. The effects of rosiglitazone, metformin, and diet with exercise in non-alcoholic fatty liver disease. Dig Dis Sci 52 (2007) 2359-2367
10. Serfaty L. Pioglitazone: the beginning of a new ear for NASH?. J Hepatol 47 (2007) 160-162
11. Pan H.J., Reifsnyder P., Vance D.E., Xiao Q., and Leiter E.H. Pharmacogenetic analysis of rosiglitazone-induced hepatosteatosis in new mouse models of type 2 diabetes. Diabetes 54 (2005) 1854-1862
12. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
13. Home P.D., Pocock S.J., Beck-Nielsen H., Gomis R., Hanefeld M., Jones N.P., et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 357 (2007) 28-38